These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. 1977 Henry H. Janeway lecture: fundamental mechanisms in combined modality therapy of cancer. Kaplan HS AJR Am J Roentgenol; 1977 Sep; 129(3):383-93. PubMed ID: 409189 [No Abstract] [Full Text] [Related]
5. New radiosensitizing regimens, drugs, prodrugs, and candidates. Vallerga AK; Zarling DA; Kinsella TJ Clin Adv Hematol Oncol; 2004 Dec; 2(12):793-805. PubMed ID: 16166960 [TBL] [Abstract][Full Text] [Related]
6. [Trial and results of improved radiotherapy for cancer. 5. Radiotherapy with simultaneous administration of radio-sensitizing agents. Administration of halogenated pyrimidine]. Tanaka N; Takahashi M Nihon Rinsho; 1972 Dec; 30(12):2655-8. PubMed ID: 4675997 [No Abstract] [Full Text] [Related]
7. [Combined curietherapy and chemotherapy]. Mazeron JJ Cancer Radiother; 1998 Dec; 2(6):781-2. PubMed ID: 9922788 [No Abstract] [Full Text] [Related]
8. [Mechanism of and dosage in the combination of ionizing radiation and substances in tumor therapy]. Streffer C Strahlentherapie Sonderb; 1978; 75():1-11. PubMed ID: 555043 [No Abstract] [Full Text] [Related]
9. A review of hypoxic cell radiosensitization. Dische S Int J Radiat Oncol Biol Phys; 1991 Jan; 20(1):147-52. PubMed ID: 1993624 [TBL] [Abstract][Full Text] [Related]
10. Clinical use of radiation sensitizing agents. Goffinet DR; Bagshaw MA Cancer Treat Rev; 1974 Mar; 1(1):15-26. PubMed ID: 4143475 [No Abstract] [Full Text] [Related]
12. Chemoirradiation: a new initiative in cancer treatment. 1991 RSNA annual oration in radiation oncology. Rotman MZ Radiology; 1992 Aug; 184(2):319-27. PubMed ID: 1620823 [TBL] [Abstract][Full Text] [Related]
13. New concepts for phase I trials: evaluating new drugs combined with radiation therapy. Deutsch E; Soria JC; Armand JP Nat Clin Pract Oncol; 2005 Sep; 2(9):456-65. PubMed ID: 16264990 [TBL] [Abstract][Full Text] [Related]
14. Polymer-conjugated paclitaxel as a radiosensitizing agent--a big step forward for combined modality therapy? Tishler RB Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):563-4. PubMed ID: 12573741 [No Abstract] [Full Text] [Related]
15. [The use of radiosensitizing agents in radiotherapy]. Franke HD Fortschr Geb Rontgenstr Nuklearmed; 1972; ():Suppl:199-201. PubMed ID: 4115508 [No Abstract] [Full Text] [Related]
16. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers. Kinsella TJ; Mitchell JB; Russo A; Morstyn G; Glatstein E Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1399-406. PubMed ID: 6381432 [TBL] [Abstract][Full Text] [Related]
17. A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation. Kinsella TJ; Russo A; Mitchell JB; Rowland J; Jenkins J; Schwade J; Myers CE; Collins JM; Speyer J; Kornblith P Int J Radiat Oncol Biol Phys; 1984 Jan; 10(1):69-76. PubMed ID: 6321412 [TBL] [Abstract][Full Text] [Related]
18. [Chemical modifiers of radiotherapy]. Asakura H Rinsho Hoshasen; 1987 Sep; 32(9):985-96. PubMed ID: 3320413 [No Abstract] [Full Text] [Related]
19. Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. Coughlin CT; Richmond RC Semin Oncol; 1989 Aug; 16(4 Suppl 6):31-43. PubMed ID: 2669136 [TBL] [Abstract][Full Text] [Related]
20. The use of radioimmunotherapy in combination with bioreductive agents. Langmuir VK Recent Results Cancer Res; 1996; 141():137-43. PubMed ID: 8722424 [No Abstract] [Full Text] [Related] [Next] [New Search]